Genotypic guidance for chemotherapy choices.
Bradbury
Jane
J
D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism; D000072224:Bcl-2-Like Protein 11; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004359:Drug Therapy, Combination; D005838:Genotype; D006801:Humans; D008565:Membrane Proteins / Q000378:metabolism; D017239:Paclitaxel / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000494:pharmacology; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D011719:Pyrazines / Q000494:pharmacology
D000972:Antineoplastic Agents, Phytogenic; D051017:Apoptosis Regulatory Proteins; C000606775:BCL2L11 protein, human; D000072224:Bcl-2-Like Protein 11; D001897:Boronic Acids; D008565:Membrane Proteins; D011480:Protease Inhibitors; D011518:Proto-Oncogene Proteins; D011719:Pyrazines; D000069286:Bortezomib; D017239:Paclitaxel